Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Imugene Limited (ASX: IMU) share price is charging higher on Tuesday morning.

At the time of writing, the immuno-oncology company's shares are up 32% to 12 cents.

Why is the Imugene share price charging higher?

Investors have been buying the company's shares following the release of a positive update on its MAST (Metastatic Advanced Solid Tumours) clinical program which is evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

According to the release, the MAST clinical program has been granted Fast Track designation from the US Food and Drug Administration (FDA).

This is good news as Fast Track designation comes with several benefits. This includes increased frequency of meetings with the FDA to discuss the drug's development plan, eligibility for Accelerated Approval and Priority Review, and a rolling review in support of a New Drug Application or Biologic License Application.

The release notes that FDA Fast Track was granted based on the promising data package from Imugene detailing phase 1 efficacy and tolerability data in patients suffering from bile duct cancer.

Bile duct cancer is a rare disease in which malignant cancer cells form in the bile ducts. They are difficult to treat and typically respond poorly to immunotherapy drugs.

Imugene's CEO and MD, Leslie Chong, was pleased with the news: Ms Chong said:

The Fast Track process of drug development is designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need, with Fast Track status often leading to earlier drug approval and access by patients.

Imugene's CMO, Dr Paul Woodard, added:

We are very encouraged to received Fast Track Designation by the FDA. We have received a high level of interest from clinicians in the emerging data from the difficult to treat bile duct cancer patient population.

The Imugene share price is still down 50% over the last 12 months despite today's gain.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »